Tsuboi Ichiro, Rajwa Pawel, Campi Riccardo, Miszczyk Marcin, Fazekas Tamás, Matsukawa Akihiro, Kardoust Parizi Mehdi, Schulz Robert J, Mancon Stefano, Cadenar Anna, Laukhtina Ekaterina, Kawada Tatsushi, Katayama Satoshi, Iwata Takehiro, Bekku Kensuke, Wada Koichiro, Karakiewicz Pierre I, Remzi Mesut, Araki Motoo, Shariat Shahrokh F
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Eur Urol Oncol. 2025 Apr;8(2):544-553. doi: 10.1016/j.euo.2024.10.008. Epub 2024 Oct 24.
While active surveillance (AS) is an alternative to surgical interventions in patients with small renal masses (SRMs), evidence regarding its oncological efficacy is still debated. We aimed to evaluate oncological outcomes for patients with SRMs who underwent AS in comparison to surgical interventions.
In April 2024, PubMed, Scopus, and Web of Science were queried for comparative studies evaluating AS in patients with SRMs (PROSPERO: CRD42024530299). The primary outcomes were overall (OS) and cancer-specific survival (CSS). A random-effects model was used for quantitative analysis.
We identified eight eligible studies (three prospective, four retrospective, and one study based on Surveillance, Epidemiology and End Results [SEER] data) involving 4947 patients. Pooling of data with the SEER data set revealed significantly higher OS rates for patients receiving surgical interventions (hazard ratio [HR] 0.73; p = 0.007), especially partial nephrectomy (PN; HR 0.62; p < 0.001). However, in a sensitivity analysis excluding the SEER data set there was no significant difference in OS between AS and surgical interventions overall (HR 0.84; p = 0.3), but the PN subgroup had longer OS than the AS group (HR 0.6; p = 0.002). Only the study based on the SEER data set showed a significant difference in CSS. The main limitations include selection bias in retrospective studies, and classification of interventions in the SEER database study.
Patients treated with AS had similar OS to those who underwent surgery or ablation, although caution is needed in interpreting the data owing to the potential for selection bias and variability in AS protocols. Our review reinforces the need for personalized shared decision-making to identify patients with SRMs who are most likely to benefit from AS.
For well-selected patients with a small kidney mass suspicious for cancer, active surveillance seems to be a safe alternative to surgery, with similar overall survival. However, the evidence is still limited and more studies are needed to help in identifying the best candidates for active surveillance.
虽然主动监测(AS)是小肾肿块(SRM)患者手术干预的一种替代方案,但其肿瘤学疗效的证据仍存在争议。我们旨在评估接受AS的SRM患者与接受手术干预的患者的肿瘤学结局。
2024年4月,在PubMed、Scopus和Web of Science数据库中检索评估SRM患者AS的比较研究(国际前瞻性系统评价注册库:CRD42024530299)。主要结局为总生存期(OS)和癌症特异性生存期(CSS)。采用随机效应模型进行定量分析。
我们纳入了八项符合条件的研究(三项前瞻性研究、四项回顾性研究和一项基于监测、流行病学和最终结果[SEER]数据的研究),共涉及4947例患者。将数据与SEER数据集合并后发现,接受手术干预的患者OS率显著更高(风险比[HR] 0.73;p = 0.007),尤其是接受部分肾切除术(PN)的患者(HR 0.62;p < 0.001)。然而,在排除SEER数据集的敏感性分析中,AS与手术干预总体的OS无显著差异(HR 0.84;p = 0.3),但PN亚组的OS长于AS组(HR 0.6;p = 0.002)。只有基于SEER数据集的研究显示CSS有显著差异。主要局限性包括回顾性研究中的选择偏倚以及SEER数据库研究中干预措施的分类。
接受AS治疗的患者与接受手术或消融治疗的患者OS相似,不过由于存在选择偏倚的可能性以及AS方案的变异性,在解释数据时需谨慎。我们的综述强调了个性化共同决策的必要性,以确定最有可能从AS中获益的SRM患者。
对于精心挑选的怀疑患有癌症的小肾肿块患者,主动监测似乎是一种安全的手术替代方案,总体生存期相似。然而,证据仍然有限,需要更多研究来帮助确定主动监测的最佳候选者。